What US Medical Studies Really Say About MOTS-c (and Why Almost No One Talks About It)

What if one of the most interesting molecules in the longevity space wasn't a new drug at all, but a peptide your own body already makes — straight from the DNA inside your mitochondria? That's the premise physician Dr. Ashley Froese (channel This Is Not Covered) lays out in her video on MOTS-c. In her words, it's one of the most interesting peptides in longevity that almost nobody talks about correctly.

This article summarizes what the research actually shows — in animal models and in early human data — along with the risks and open questions worth knowing before getting excited.

What exactly is MOTS-c

MOTS-c is a 16-amino-acid peptide produced from DNA inside the mitochondria — the small organelles responsible for cellular energy production. It was discovered in 2015, and its name stands for "Mitochondrial Open Reading Frame of the 12S rRNA Type-C."

More important than the name is what it does: MOTS-c is a signaling molecule. Mitochondria use it to send a message to the rest of the cell — and that message can trigger a cascade of metabolic changes.

When the body naturally produces MOTS-c

MOTS-c is produced at a baseline level continuously, but its synthesis spikes sharply in response to metabolic stress, particularly:

• physical exertion and exercise — the biggest and fastest spike, with levels staying elevated for hours afterward to support metabolic recovery,
• fasting or caloric restriction,
• low tissue oxygen levels,
• extreme thermal changes (heat or cold) that require metabolic adaptation.

Notably, MOTS-c levels naturally decline with age, which may be one reason mitochondrial communication and metabolic flexibility both decline as we get older.

How MOTS-c works in the body

According to the video, MOTS-c acts as a signal that essentially forces the cell to reset its metabolism to survive stress and prepare for the future. Specifically, it:

• activates AMPK, the body's primary energy sensor, increasing insulin sensitivity and helping cells pull glucose out of the bloodstream more efficiently,
• helps clear stagnant fatty acids that otherwise block insulin receptors,
• unlocks fatty acid oxidation, allowing more fat to be used as fuel in the mitochondria,
• triggers mitochondrial biogenesis — the replication of mitochondrial DNA and assembly of new mitochondria — increasing ATP output and metabolic waste clearance,
• supports muscular endurance by shifting muscle cells toward a more endurance-oriented profile, which is why MOTS-c is sometimes called an "exercise mimetic."

What the animal research shows

Dr. Froese cites several animal studies worth noting:

• In the original 2015 discovery study, mice on a high-fat diet given MOTS-c never developed obesity or insulin resistance, unlike the control group. Mice that had already developed obesity and insulin resistance saw those conditions reversed after receiving MOTS-c.
• In older mice, MOTS-c administration significantly slowed age-related physical decline, improved endurance capacity, and enhanced overall healthspan.
• In damaged and dystrophic muscle tissue, MOTS-c significantly boosted energy production.
• In diabetic rats, MOTS-c reduced cardiac wall thickness by roughly 8% and improved heart efficiency.
• In a mouse model of induced menopause (via ovary removal), MOTS-c slowed bone breakdown and triggered stem cells to build new bone — one reason it's being explored as a potential future treatment for osteoporosis.

What human research shows

Alongside animal models, some human data exists too:

• A study from Japan found that people with naturally higher MOTS-c levels tend to have lower levels of myostatin, a protein that limits muscle growth — suggesting a potential link to less restricted muscle growth.
• Women with PCOS and people with severe sleep apnea show notably lower MOTS-c levels than average.
• One study found low MOTS-c levels in the blood and tumor cells of women with ovarian cancer — and adding MOTS-c to those cancer cells aggressively slowed disease progression in that model.

Risks and what we still don't know

To keep the picture balanced, here's what Dr. Froese flags directly:

• MOTS-c has a reputation, from real-world reports, for causing more pronounced injection-site welts than other peptides, sometimes lasting days to weeks.
• Some users report feeling overstimulated, jittery, or anxious.
• Blood sugar crashes have been reported — since MOTS-c activates AMPK the same way metformin and berberine do, stacking these together needs caution.
• There's a theoretical concern that activating certain metabolic adaptation genes could, under specific conditions, feed cancer cells energy or block their death. This isn't proven, but it's a legitimate open question.
• Long-term human safety data is lacking.
• In the United States, MOTS-c is not currently FDA-approved for human use. It exists in a research-use-only regulatory category, and marketing it for human consumption is not permitted.

Bottom line

Animal studies on MOTS-c are genuinely compelling — better insulin sensitivity, stronger muscles, healthier hearts and bones, and slower age-related decline. Early human data (myostatin, PCOS, sleep apnea, levels in cancer patients) points in a similar direction, though it remains largely observational rather than large-scale clinical trial evidence. MOTS-c is a good example of mitochondria acting as active signaling hubs, not just cellular power plants — but as Dr. Froese herself puts it, this is still a waiting game until the compound becomes more accessible and better studied.

Curious about other research peptides and how they work? You'll find an overview on our research compound information page, which links out to individual products for research use.

Sources

1. Dr. Ashley Froese – "The Truths about MOTS-c Nobody is Talking About", YouTube, This Is Not Covered: https://www.youtube.com/watch?v=wH8C8c_NbWE
2. Reynolds et al., "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis", Nature Communications, 2021: https://pmc.ncbi.nlm.nih.gov/articles/PMC7817689
3. Wan et al., "Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging", Journal of Translational Medicine, 2023: https://pmc.ncbi.nlm.nih.gov/articles/PMC9854231/